Curative Biotechnology Inc Cash Flow Conversion Efficiency
Curative Biotechnology Inc cash flow conversion efficiency. Based on the latest financial reports, Curative Biotechnology Inc (CUBT) has a cash flow conversion efficiency ratio of 0.031x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-193.12K) by net assets ($-6.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Curative Biotechnology Inc (2013–2025)
Cash flow conversion efficiency of Curative Biotechnology Inc from 2013 to 2025. This chart illustrates how Curative Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Curative Biotechnology Inc (CUBT) stock price for real-time trading data and today's change.
Curative Biotechnology Inc Cash Flow Conversion Ratio Explained
Curative Biotechnology Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Curative Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Curative Biotechnology Inc ranked by their cash flow conversion efficiency. Also see how much is Curative Biotechnology Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Blackrock Smaller Companies Trust PLC
LSE:BRSC
|
0.015x |
|
Solis Minerals Ltd
V:SLMN
|
-0.043x |
|
Damodar Industries Limited
NSE:DAMODARIND
|
0.146x |
|
RECYCLICO BATTERY METALS
F:ID4
|
-0.015x |
|
Mexican Gold Corp
V:MEX
|
0.953x |
|
Atlas Cycles (Haryana) Limited
NSE:ATLASCYCLE
|
0.001x |
|
Slam Exploration Ltd.
V:SXL
|
-0.046x |
|
FG Financial Group
NASDAQ:FGF
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Curative Biotechnology Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Curative Biotechnology Inc from 2013 to 2025. Review Curative Biotechnology Inc (CUBT) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-6.09 Million | $-868.87K | 0.143x | -31.43% |
| 2024-12-31 | $-4.91 Million | $-1.02 Million | 0.208x | +34.46% |
| 2023-12-31 | $-3.14 Million | $-486.58K | 0.155x | +107.00% |
| 2022-12-31 | $-20.53 Million | $-1.54 Million | 0.075x | -23.70% |
| 2021-12-31 | $-16.36 Million | $-1.60 Million | 0.098x | +133.19% |
| 2020-12-31 | $-4.52 Million | $-190.09K | 0.042x | +9914.88% |
| 2019-12-31 | $-357.33K | $-150.00 | 0.000x | +92.90% |
| 2018-12-31 | $-689.28K | $-150.00 | 0.000x | -4.34% |
| 2017-12-31 | $-659.37K | $-150.00 | 0.000x | -97.54% |
| 2016-12-31 | $-636.38K | $-5.89K | 0.009x | +393.09% |
| 2015-12-31 | $-618.98K | $1.96K | -0.003x | -111.64% |
| 2014-12-31 | $-773.80K | $-20.99K | 0.027x | -46.45% |
| 2013-12-31 | $-704.28K | $-35.68K | 0.051x | -- |
About Curative Biotechnology Inc
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying… Read more